Mycotoxins and Mitochondrial Health

Mycotoxins are secondary metabolites produced by filamentous fungi, chiefly Aspergillus, Fusarium and Penicillium, that contaminate food crops, stored grain and water-damaged buildings. More than 300 are known, and many are heat-stable.¹ Mitochondria, which generate most cellular ATP, carry their own genome (mitochondrial DNA, mtDNA) and translation machinery. In yeast and cell models, trichothecenes inhibit mitochondrial protein synthesis at doses below those that suppress cytosolic translation, with downstream changes in membrane potential and reactive oxygen species (ROS).³ ⁴ In people, the picture is less complete. Mould exposure is associated with worse asthma, but the links to autoimmune disease and inflammatory bowel disease rest on limited data and cannot yet be called causal.² Urinary mycotoxin tests, meanwhile, have not been validated for clinical use.⁵ ⁶ 

Mycotoxins in Clinical Practice

A patient presents with fatigue, impaired concentration and recurrent sinus symptoms, and mentions almost in passing that the family moved into a rental with a history of water damage. Most clinicians will recognise the pattern, and will also recognise how difficult it is to know what to make of it. Mitochondria offer a biologically plausible point of contact between mould exposure and multisystem symptoms, which is why the topic recurs in integrative and functional practice. 

The exposure itself is common. Roughly a quarter of the world's harvested crops are contaminated with mycotoxins each year, and the compounds most often detected in food (aflatoxins, trichothecenes, zearalenone, fumonisins, ochratoxins and patulin) are largely heat-stable.¹ Mycotoxins are also systemically bioavailable whether they are swallowed, inhaled or absorbed through the skin, and they can cross or weaken epithelial, gut and blood–brain barriers.² 

The difficulty lies in the gap between mechanism and measurement. Cell studies describe credible mitochondrial targets, but human evidence is thinner, the diagnostic framework for mould-related illness (including so-called toxic mould syndrome) is contested, and commercial testing is poorly standardised.² ⁵ ⁶ Clinicians need a model that is mechanistically informed and explicit about where the evidence ends.  

The Challenge: A Toxin That Needs No Obvious Entry Point

Moulds make mycotoxins as secondary metabolites, and the main producers in food are Aspergillus, Fusarium and Penicillium.¹ Once ingested or inhaled, these small molecules distribute widely, so tissues with high energy demand (liver, kidney, gut lining, immune cells, brain) meet them at concentrations set by dose, duration and individual handling capacity. The cell’s problem is that many mycotoxins act on core processes shared by all eukaryotes, such as protein synthesis, and mitochondria contain a bacteria-like version of that machinery. 

Mitochondrial Protein Synthesis As a Target

Mitochondria make only 13 proteins from their own DNA in humans, but these are essential subunits of the respiratory chain. A yeast study by Bin-Umer and colleagues tested three trichothecenes (trichothecin, T-2 toxin and diacetoxyscirpenol) and found that cells were more sensitive when they depended on respiration (grown on glycerol) than when they could ferment glucose.³ Cells lacking mtDNA altogether (rho0) tolerated far higher doses, in some cases by an order of magnitude or more.³ At low doses, the toxins inhibited mitochondrial translation without suppressing total cellular translation, and they did so directly in isolated mitochondria.³ The authors concluded that mitochondrial translation is a primary target, not a downstream consequence of membrane damage.³ 

Cells initially respond with measurable shifts. In the yeast data, low doses produced a transient rise in membrane potential and ROS at six hours, followed by a fall by eighteen hours, whereas high doses fragmented the mitochondrial network and cut membrane potential by 50–83%.³ This pattern is consistent with an adaptive phase that gives way to failure once exposure exceeds capacity, although the study did not test recovery. A broader review of trichothecene toxicity describes related effects in mammalian systems, including mitochondrial ROS, mitochondria-dependent apoptosis, altered respiratory chain function and changes in biogenesis signalling.⁴ 

These experiments used yeast and micromolar concentrations, and the authors themselves note the model is not mammalian.³ They show that a mitochondrial target exists, but they don't show that typical dietary or indoor exposures in people reach that threshold. Four mechanisms recur in the literature: 

1. Inhibition of mitochondrial translation: Trichothecenes are best known for blocking ribosomal protein synthesis in the cytosol.¹ Yeast data indicate that they also block the mitochondrial ribosome at lower concentrations, which would reduce production of respiratory chain subunits encoded by mtDNA.³ Evidence level: mechanistic, non-mammalian. 

2. Altered membrane potential and ROS: Membrane potential (ΔΨM) is the electrical gradient across the inner mitochondrial membrane that drives ATP production. In yeast, trichothecenes changed ΔΨM and ROS in a dose- and time-dependent manner, with a transient rise at low doses and a fall at high doses.³ Earlier reports link T-2 toxin, enniatins and fumonisin B1 to mitochondrial dysfunction in other models.³ Evidence level: mechanistic, mixed models. 

3. Mitochondrial apoptosis and dynamics: Trichothecenes such as T-2 and deoxynivalenol (DON) have been reported to trigger the mitochondrial pathway of cell death and to affect biogenesis regulators including PGC-1α and mTOR signalling.⁴ In yeast, high doses also fragmented the mitochondrial network.³ Evidence level: cell and animal studies. 

4. Oxidative stress feeding immune signalling: Mycotoxins can activate the inflammasome and NF-κB, and ochratoxin A has been linked to ROS generation with altered Nrf2 handling.² Mitochondrial damage has also been proposed as one route to anti-mitochondrial autoantibody formation in autoimmune disease, although this remains a hypothesis built largely on animal and small human studies.² Evidence level: mechanistic, with limited human data. 

These pathways are not unique to mycotoxins - aflatoxin B1 acts mainly after metabolic activation to an epoxide that binds DNA and proteins, including mitochondrial nucleic acids, and its carcinogenicity is established by IARC classification (Group 1) through largely non-mitochondrial routes.¹ The mitochondrial story therefore sits alongside, not instead of, other toxicity mechanisms. 

Real-World Example 

A woman in her forties presents with chronic fatigue, poor concentration and recurrent sinusitis that began after she moved into a rental with prior water entry. She also stores bulk grain at home. A commercial urinary mycotoxin panel reports low-level ochratoxin A. 

• The mechanistic literature supports a plausible link between mould metabolites and mitochondrial stress, but the assay cannot bear the interpretive load. The US Navy and Marine Corps Force Health Protection Command notes that no urine mycotoxin test is FDA-approved, that no reference ranges predict disease, that results mostly reflect ingestion rather than inhalation, and that mycotoxins are not cumulative, with half-lives of hours to days.⁶

• Background detection is also common: an expert critique cites ochratoxin A in 95% of a Bangladeshi cohort of pregnant women and notes that no prospective study shows that test-guided intervention improves outcomes.⁵ 

• A more defensible workup starts with the building, the diet and the differential. Document visible damp, odour, the timing of symptom onset relative to occupancy, and grain, nut and seed storage.

• Consider common contributors to the same presentation, such as anaemia, thyroid dysfunction, sleep disorders and depression.

• Remediating the water source and improving food storage address exposure directly, and response can be tracked through symptoms and function. The mitochondrial hypothesis then shapes how resilience is supported, without being claimed as confirmed in this individual. 

The conditions below have been studied in relation to mycotoxin or mould exposure: